Your browser doesn't support javascript.
loading
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
Guffanti, F; Alvisi, M F; Anastasia, A; Ricci, F; Chiappa, M; Llop-Guevara, A; Serra, V; Fruscio, R; Degasperi, A; Nik-Zainal, S; Bani, M R; Lupia, M; Giavazzi, R; Rulli, E; Damia, G.
Afiliação
  • Guffanti F; Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Alvisi MF; Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Anastasia A; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Ricci F; Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Chiappa M; Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Fruscio R; Clinic of Obstetrics and Gynecology, Department of Medicine and Surgery, San Gerardo Hospital, University of Milan Bicocca, Monza, Italy.
  • Degasperi A; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Box 197, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK.
  • Nik-Zainal S; Academic Laboratory of Medical Genetics, Lv 6 Addenbrooke's Treatment Centre, Addenbrooke's Hospital, Box 238, Cambridge, CB2 0QQ, UK.
  • Bani MR; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Box 197, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK.
  • Lupia M; Academic Laboratory of Medical Genetics, Lv 6 Addenbrooke's Treatment Centre, Addenbrooke's Hospital, Box 238, Cambridge, CB2 0QQ, UK.
  • Giavazzi R; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Rulli E; Unit of Gynecological Oncology Research, European Institute of Oncology, Milan, Italy.
  • Damia G; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Br J Cancer ; 126(1): 120-128, 2022 01.
Article em En | MEDLINE | ID: mdl-34732853
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Cisplatino / Proteína BRCA1 / Proteína BRCA2 / Rad51 Recombinase / Recombinação Homóloga Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Cisplatino / Proteína BRCA1 / Proteína BRCA2 / Rad51 Recombinase / Recombinação Homóloga Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article